100% satisfaction guarantee Immediately available after payment Both online and in PDF No strings attached
logo-home
Samenvatting Les 2 'Drug discovery process, therapeutic modalities' $7.80   Add to cart

Summary

Samenvatting Les 2 'Drug discovery process, therapeutic modalities'

 6 views  0 purchase
  • Course
  • Institution

This document includes the summary of Lesson 2 (info slides with notes) of the “Preclinical drug research” course.

Preview 2 out of 9  pages

  • September 7, 2024
  • 9
  • 2023/2024
  • Summary
avatar-seller
Lecture 2: 2/10
Therapeu(c modali(es
Types of therapeu.cs
- Several therapeu-cal modali-es available
- Spectrum becomes broader
- Conven-onal = all types of interven-on aimed at allevia-ng and eradica-ng the effects of
disease
o Improve disease symptoms and/or prognosis
o Alleviate effects of exis-ng disease
o Directed towards disease preven-on
o Achieve permanent cure
- Non-conven-onal
o Nutraceu-cals = range of dietary prepara-ons
§ slimming diets, diets with minerals, vitamins, fiber, an-oxidants, …
§ some scien-fic ra-onale
§ not subjected to formal regulatory approval
§ Ceu-cals are oGen not regulated. Sold you as products to help to lose weight, for
example
§ In the end you can’t be sure what the effect/benefit is of nutraceu-cals
§ Also safety is not sure
o Cosmeu-cals = cosme-cs supplemented with some ac-ve (?) substances
§ reduce skin wrinkles, promote hair growth, …
§ liNle or no scien-fic ra-onale
§ free sales (but major market !!)
§ Free sale -> major market -> lot of publicity

Current therapeu.cs
Conven&onal therapeu&c drugs
- Small molecules groups
o Most of current drugs (Pharmacopoeia)
o Chemicals
o Small molecular size -> important for the phamacokine-cs, oral uptake
o Small molecular drugs/en--es
o Advantages
§ Several targets -> also a disadvantage -> less specific, side/adverse effects
§ Accepted by profession and community
§ Various routes of administra-on
§ Longterm pharmaceu-cal experience
o Disadvantages
§ It becomes more difficult to find new small molecule drugs that differen-ate
them from others
§ Broader spectrum -> lower selec-vity -> toxicity
§ Pharmacokine-c limita-ons

, • Phase I clinical trial and you need a certain plasma concentra-on -> stop
with development or change the formula-on to increase the plasma
concentra-on (and efficacy)
§ Frequent poor oral absorp-on -> improve this by adding extra substances ->
vehicles are used for this (some of this vehicles are toxic by themselves)
- Natural products or semi-synthe-cally derived)
o an-bio-cs, an-cancer, opiates, sta-ns,

Biopharmaceu&cals
- = Noval therapeu-c modali-es
- = Non small molecule drugs
- Several groups
o Pep-de/protein mediators
o Blood cloZng factors
o Enzymes
o An-bodies (an-sera, an-toxins, mAb)
o Vaccines (inac-vated, aNenuated, subunit)
o Cells/-ssues (stem cells, graG- and transplant surgery)
- Advantages
o Higher selec-vity than small molecules drugs -> open new therapeu-cal op-ons
o More straigh]orward discovery
§ You really focus on the target and design it for the target -> less toxicity
o Unexpected toxicity is less common
o Higher product quality
- Disadvantages
o Much more expensive
o Lack of oral ac-vity and short half-life
o Designed for the human pharmacological target -> no good animal model

Beyond current biopharmaceu.cals …
Gene therapy
- Correc-ng gene-c defects by altering gene-c material of cells by recombinant DNA
technology
o Introduce new genes to replace missing or dysfunc-onal ones (virus vector: non-
integrated vs. integrated DNA)
o Aim at single-gene disorders (cys-c fibrosis, haemophilia) and cancer
o Restricted to soma-c cell treatments (ban on germ-cell gene therapy experiments
- Not many gene therapy products licensed yet for clinical use
- Disappoin-ng prospects (long-term safety, gene-delivery systems, …
- Become more and more important
- OGen a rare disease -> orphan drug
- Several ways of working with this
- Broad term: for example you are going to block the transcrip-on of the gene and later the
transla-on of the mRNA to the proteins
- An-sense DNA
o oligonucleo-de sequence complementary to part of a known mRNA sequence ->
selec-ve blocking of expression
o but:

The benefits of buying summaries with Stuvia:

Guaranteed quality through customer reviews

Guaranteed quality through customer reviews

Stuvia customers have reviewed more than 700,000 summaries. This how you know that you are buying the best documents.

Quick and easy check-out

Quick and easy check-out

You can quickly pay through credit card or Stuvia-credit for the summaries. There is no membership needed.

Focus on what matters

Focus on what matters

Your fellow students write the study notes themselves, which is why the documents are always reliable and up-to-date. This ensures you quickly get to the core!

Frequently asked questions

What do I get when I buy this document?

You get a PDF, available immediately after your purchase. The purchased document is accessible anytime, anywhere and indefinitely through your profile.

Satisfaction guarantee: how does it work?

Our satisfaction guarantee ensures that you always find a study document that suits you well. You fill out a form, and our customer service team takes care of the rest.

Who am I buying these notes from?

Stuvia is a marketplace, so you are not buying this document from us, but from seller evagoormans. Stuvia facilitates payment to the seller.

Will I be stuck with a subscription?

No, you only buy these notes for $7.80. You're not tied to anything after your purchase.

Can Stuvia be trusted?

4.6 stars on Google & Trustpilot (+1000 reviews)

62890 documents were sold in the last 30 days

Founded in 2010, the go-to place to buy study notes for 14 years now

Start selling
$7.80
  • (0)
  Add to cart